61 results
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
4 Jan 24
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
4:01pm
, while also providing significant market opportunities for Cocrystal.”
CDI-988 targets a highly conserved region in the active site of the main 3CL
8-K
EX-99.2
COCP
Cocrystal Pharma Inc
29 Nov 23
Regulation FD Disclosure
8:00am
machinery is targeted. CC-42344 targets the influenza polymerase, an essential replication enzyme with several highly essential regions common
8-K
EX-99.1
eq95u5cag2ged18s
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
8-K
EX-99.1
8ib ccj1rb
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm
424B5
wtvp9sco23hvmx
15 Jun 23
Prospectus supplement for primary offering
4:54pm
8-K
EX-99.1
lybqzu8e69nz
15 May 23
Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:00am
8-K
EX-99.1
fst nk69u6qo3yi3kcnq
26 Oct 22
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
8:00am
424B5
es2b6xa
5 May 21
Prospectus supplement for primary offering
4:01pm